| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Astria Therapeutics, Inc. (ATXS) has 8 insiders with recent SEC Form 4 filings, including 12 buys and 3 sells. ATXS is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| Dir | 26.6K | - | - | |
| Dir | 26.6K | - | - | |
| Dir | 26.6K | - | - | |
| Dir | 26.6K | - | - | |
| Dir | 26.6K | - | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Apr 1, 2024 | Morabito Christopher61 | Chief Medical Officer | Sale+OE | 10,000 | $13.59 | $135,939.00 | -100% | -31.5% | -60.0% | |
| Feb 1, 2024 | Perceptive Advisors LLC51 | Director | Buy | 2,481,350 | $12.09 | $29,999,521.50 | +103.7% | -29.9% | -42.0% | |
| Jan 29, 2024 | Morabito Christopher61 | Chief Medical Officer | Sale+OE | 10,000 | $11.14 | $111,364.40 | -100% | -24.3% | -38.0% | |
| Dec 21, 2023 | Perceptive Advisors LLC51 | Director | Buy | 740,000 | $6.20 | $4,588,000.00 | +44.8% | +152.3% | +53.5% | |
| Oct 16, 2023 | Perceptive Advisors LLC51 | Director | Buy | 1,074,608 | $6.51 | $6,999,996.51 | +49.1% | +15.7% | +80.7% | |
| Dec 19, 2022 | Perceptive Advisors LLC51 | Director | Buy | 908,265 | $11.01 | $9,999,997.65 | +698.4% | +1.0% | -44.4% | |
| Nov 19, 2021 | Komjathy Andrew | Chief Commercial Officer | Buy | 100 | $6.70 | $669.50 | New | -3.5% | +32.7% | |
| Jun 30, 2015 | Svlsf V, LLC | 10% Owner | Buy | 391,090 | $12.00 | $4,693,080.00 | +15.9% | - | - | |
| Jun 30, 2015 | Clarus Lifesciences Ii, L.P. | 10% Owner | Buy | 376,695 | $12.00 | $4,520,340.00 | +15.9% | - | - | |
| Jun 30, 2015 | George Jean | Director | Buy | 258,776 | $12.00 | $3,105,312.00 | +15.9% | - | - |